Microsatellite Instability (MSI) status is an established predictive biomarker for the treatment of the anti-programmed death 1 (PD-1) antibody. The current approach to determine the MSI status in tumours requires matched normal DNA. Some mononucleotide microsatellite markers are known to have few variant alleles in both Caucasians and Asians. Therefore, the length of these microsatellite makers is almost confined within the quasi-monomorphic variation range (QMVR). Considering the application of MSI testing for various types of cancers, a simple, sensitive and inexpensive method is desired. This study assessed the clinical utility of the QMVR for determining the MSI status in patients with unresectable metastatic colorectal cancer (mCRC). The study enrolled 435 patients with mCRC. The concordance of the MSI status in mCRC between the standard method using tumour DNA plus matched normal DNA and the testing method using only tumour DNA was evaluated. Eleven (2.5%) MSI-high cases were detected by both the standard and testing methods. The sensitivity and specificity of the testing method were both 100%, indicating complete concordance between the methods. Among the mononucleotide markers, three and two patients showed discordance for NR-21 and BAT-25, respectively. Results from MSI testing with normal tissue indicated that four of five patients had rare germline variants outside the QMVR. For BAT-26, NR-24 and MONO-27, all patients showed complete concordance. Using the QMVR, the MSI status of mCRC can be determined without matched normal DNA.
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| INTRODUCTION
Microsatellite instability (MSI) is defined as alteration of the lengths of repetitive sequences in tumour DNA, which is not observed in corresponding germline DNA. MSI is recognised as a hallmark of mismatch repair (MMR) deficiency. 1, 2 that patients with advanced solid tumours are more frequently undergoing PD-1 blockade treatment according to these new indications, the development of a simple, sensitive and inexpensive method to assess MMR deficiency is desired. the MSI status of Caucasian CRC patients could be retrospectively determined using the QMVR, with high sensitivity and specificity. 8, 9 According to three large Japanese cohorts, the frequencies of variant alleles for the five mononucleotide markers are very low (Table S1 ).
10
A pilot study using blood samples from 149 healthy Japanese individuals suggested that the QMVR of each marker was generated in base pairs (bps) as the mean size of each marker ± 3 bps, which is consistent with the findings in previous studies (Table S2) . 9, 10 This suggests that the QMVR might be useful for determining the MSI status in not only Caucasian patients but also Asian patients. However, the clinical utility of the QMVR has not been verified prospectively in patients with unresectable mCRC. The present study aimed to assess the clinical utility of the QMVR for determining the MSI status in patients with unresectable mCRC.
| MATERIAL AND METHODS

| Patients
Since February 2016, the multi-institutional joint study called GI-SCREEN CRC-MSI is being conducted to investigate the MSI status of Japanese patients with mCRC (UMIN000020437). Promega MSI tests using DNA isolated from both tumour tissue and paired normal tissue were performed as a standard method in the GI-SCREEN CRC-MSI study. and were analysed using GeneMapper software (Life Technologies) to determine the MSI status. The QMVR of each marker generated from 149 healthy Japanese individuals was used as the normal reference range for determining the MSI status in the testing method of the sub-study (Table S2) As all registration numbers for the GI-SCREEN CRC-MSI study were double encoded before this sub-study, the testing method using only tumour samples was conducted blindly without any information with regard to the MSI status by the standard method.
| MSI determination using the QMVR
| Statistical analysis
Endpoints were analysed by creating a 2 × 2 cross-tabulation table for the number of specimens in which the MSI status was determined to be MSI-H (positive) and MSS/MSI-L (negative) using the testing method and the standard method. The primary endpoints of this sub-study were the sensitivity (positive conformity rate) and specificity (negative conformity rate) of the testing method when compared with the standard method. The testing method would be
considered effective if the decision rule previously established with regard to sensitivity is fulfilled and if specificity is ≥90% (Table S3) .
As secondary endpoints, the concordance rate, positive-predictive value and negative-predictive value were evaluated.
| Repeated PCR examination
As a post hoc analysis, both the standard and testing MSI methods were performed again by using the same tumour and normal DNA samples as in the first evaluation, when the discordant markers were observed.
| RESULTS
| Patient characteristics
Between February 2016 and November 2016, the results of MSI testing were obtained from 474 patients in the GI-SCREEN CRC-MSI study. Of these patients, 38 did not fulfil the eligibility criteria, and they were excluded. Thus, 436 patients were eligible for the GI-SCREEN-CRC MSI sub-study. However, one patient was excluded because MSI could not be analysed using the newly developed MSI kit. Finally, 435 patients were eligible for the analysis set ( Figure 1 ).
The median patient age was 66 years, and 248 (57.0%) patients were male. The analysis involved 368 (84.6%) primary and 67 (15.4%) metastatic specimens (Tables 1, S4 ).
| Comparison of the MSI status between the standard and testing methods
Among the 435 patients, 11 (2.5%) had tumours classified as MSI-H with the standard method, 10 of which were in right side colon and 1 were in rectum, respectively. These tumours were also classified as MSI-H with the testing method. The remaining 424 patients had tumours classified as MSS/MSI-L with the standard method. These tumours were also classified as MSS/MSI-L with the testing method.
Therefore, the sensitivity and specificity of the MSI status with the testing method were both 100%. The concordance rate, positive-predictive value and negative-predictive value were all 100% ( Table 2 ). (Table 3 ).
|
In the post hoc analysis, we re-evaluated microsatellite unstable markers in the five discordant cases using the same tumour and normal DNA samples. The same microsatellite alterations were observed in all five cases.
| DISCUSSION
We verified the clinical utility of the QMVR in patients with mCRC.
The sensitivity and specificity of the testing method and standard method were perfectly concordant. As germline variants involving the five assessed mononucleotide markers are very rare in Japanese individuals, the QMVR of each marker was useful as a reference in MSI testing.
Five patients had only one discordant marker (NR-21 in three and BAT-25 in two) among the 2 methods. Repeated tests showed the same results, suggesting that the discordant results were not F I G U R E 1 Results of Microsatellite instability (MSI) testing were obtained from 474 patients in the GI-SCREEN CRC-MSI study. Of these patients, 38 did not fulfil the eligibility criteria, and they were excluded. Thus, 436 patients were eligible for the GI-SCREEN-CRC MSI sub-study. However, one patient was excluded because MSI could not be analysed using the newly developed MSI kit. Finally, 435 patients were eligible for the analysis set BANDO ET AL.
| 3413 associated with artefacts. Of the five patients, four had different sizes of microsatellites outside the QMVR in the germline. In these patients, the testing method showed false positive. According to the frequencies of variant alleles in NR21 and BAT25 in Japanese cohorts (Table S1 ), these discordant rates can be considered reason- (Table S2) . 9, 10 These results suggest that MSI kits using the same QMVRs could be applied in both Asian and Caucasian patients. However, further studies will be needed to clarify the clinical utility of the new MSI-kit for Caucasian patients.
The present study has some limitations. Immunohistochemistry (IHC) testing was not performed to compare PCR-based testing.
Comparisons between the results with the new MSI kits and those with IHC testing may support the robustness of the newly developed PCR-based testing approach, as 13% of MSI-H cases were reported to have an indefinite/equivocal staining pattern in IHC testing. 11 Furthermore, as MSI-H cases are rare among patients with mCRC, only 11 (2.5%) cases were included in this sub-study. Before starting this sub-study, we estimated the approximately 2%-4% of MSI-H cases would be included. For this situation, even if the sensitivity of the testing method is low, the concordance rate is likely to be high. As we consider evaluation using the concordance rate is inappropriate to accurately evaluate the clinical performance, both the sensitivity and specificity of the testing method were decided as primary endpoint. We also made 'the decision rule for sensitivity' before starting this sub-study to accurately evaluate the sensitivity using small number of MSI-H cases (Table S3) In one patient, the BAT-26 status was not determined.
3414 | testing method is effective because the decision rule regarding sensitivity is fulfilled and specificity is ≥90%. Considering the application of MSI testing for various types of inoperable advanced solid tumours, a simple and inexpensive method is desired. The QMVR can be used as a reference of MSI testing and can help reduce the cost of PCR examination.
In conclusion, by using the QMVR, the MSI status of patients with mCRC can be determined without matched normal DNA, and the same QMVR might be applicable to both Asian and Caucasian patients.
